-

Inocras and Center for Data Driven Discovery in Biomedicine Enter Collaborative Research Agreement to Advance Sinonasal Cancer Research

SAN DIEGO--(BUSINESS WIRE)--Today, Inocras announced the signing of a groundbreaking Collaborative Research Agreement with the Center for Data Driven Discovery in Biomedicine (D3b) to advance research into rare sinonasal cancers. Under the agreement, Inocras will conduct Whole Genome Sequencing (WGS) and bioinformatic analysis on rare sinonasal cancer samples provided by D3b.

“We hope that this partnership represents a significant step forward in our understanding of the genetic underpinnings of sinonasal cancers, which remain challenging to diagnose and treat due to their rarity,” said Dr. Garret W. Choby, Associate Professor

Share

The leadership team at the Center for Data Driven Discovery in Biomedicine (D3b) - Phillip “Jay” Storm, Adam Resnick, and Jena Lilly - are spearheading this collaboration with researchers from prestigious academic and medical institutions as part of the Cole-Reagins Registry for Sinonasal Cancer (CORSICA) Project. CORSICA, funded by the Natalie A. Cole-Reagins Family Foundation, is a translational research initiative dedicated to improving the study and treatment of sinonasal cancer by linking biospecimens with a clinical registry to assess long-term patient outcomes across 10 research sites nationwide.

The collaboration’s initial focus will be on performing WGS and bioinformatic analysis on 30 sinonasal mucosal melanoma cases. Each case will include both tumor and germline samples, enabling Inocras to generate comprehensive WGS data and CancerVision™ reports to deepen the understanding of the disease’s genetic foundation.

“We hope that this partnership represents a significant step forward in our understanding of the genetic underpinnings of sinonasal cancers, which remain challenging to diagnose and treat due to their rarity,” said Dr. Garret W. Choby, Associate Professor of Otolaryngology – Head and Neck Surgery and Neurological Surgery at the University of Pittsburgh School of Medicine. “By leveraging advanced genomics and bioinformatics, we aim to uncover critical genetic insights that could ultimately inform new therapeutic strategies for our patients.”

The findings from this collaboration are expected to contribute to multiple shared publications, presentations, and scientific posters. Additionally, this initiative paves the way for future collaborations between Inocras, D3b, CORSICA, and other academic institutions, with the long-term goal of establishing WGS and bioinformatics-driven insights as a standard of care for mucosal melanomas and other sinonasal cancers.

About Inocras Inc.:

Inocras is an AI-driven company that specializes in delivering critical insights to cancer and rare disease patients through whole genome sequencing and bioinformatics. The company offers its whole genome testing products, CancerVision, RareVision and MRDVision, and provides research services for pharmaceutical and biotechnology companies as well as research organizations through its CAP/CLIA lab, powered by its proprietary, IP-protected bioinformatics pipeline. Inocras is dedicated to unlocking the potential of whole genome data to enable precision health for everyone. For more information, please visit inocras.com and follow the Inocras LinkedIn page.

Contacts

Media contact:
Jordan Younis
jyounis@inocras.com

Inocras Inc.


Release Versions

Contacts

Media contact:
Jordan Younis
jyounis@inocras.com

Social Media Profiles
More News From Inocras Inc.

Inocras Unveils New MRDVision™ Data, Demonstrating Industry-leading Sensitivity in Head-to-Head Clinical Study Against Leading MRD NGS Assay

SAN DIEGO--(BUSINESS WIRE)--Today, Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, announced MRDVision, its solution for minimal residual disease (MRD) detection, validated to CLIA standards. The assay, previously available for research use only, is now ready for use in clinical settings, redefining the standard in MRD testing by enabling ultra-sensitive detection of circulating tumor DNA (ctDNA) with a simulated limit of detection (LOD) as low as 1 part per million (ppm)...

Fore Genomics Partners with Inocras to Launch Pediatric Genetic Health Screening and Newborn Sequencing

SAN DIEGO--(BUSINESS WIRE)--Today, Fore Genomics, a leader in pediatric genetic health screening, announced a strategic partnership with Inocras, a leading innovator in whole genome sequencing (WGS) and AI-powered genetic analysis technologies, to enhance Fore’s proprietary pediatric and newborn health screening services. This collaboration marks a significant step towards improving early detection and intervention for a large number of pediatric-onset genetic conditions, with the initial rollo...

Inocras earns ISO 15189 accreditation from ANSI ASQ National Accreditation Board (ANAB)

SAN DIEGO--(BUSINESS WIRE)--ANSI ASQ National Accreditation Board (ANAB) has awarded whole genome sequencing and bioinformatics company, Inocras Inc., accreditation to the ISO 15189 standard under its ISO 15189 Medical Laboratories Accreditation Program. Notably, Inocras is one of very few companies in the world with a CAP/CLIA/ISO 15189 accredited lab performing whole genome sequencing for cancer. This accreditation is based on the International Organization for Standardization (ISO) 15189 Sta...
Back to Newsroom